DELIVER Results – Scott D. Solomon, MD

Investigator Scott D. Solomon, MD recaps the results of the DELIVER trial, which found that among individuals with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death.

Brain & Body Power Free Trial

You May Also Like

Leave a Reply

Your email address will not be published.